{"id":"inh-preventive-therapy","safety":{"commonSideEffects":[{"rate":"1-2","effect":"Peripheral neuropathy"},{"rate":"0.5-3","effect":"Hepatotoxicity"},{"rate":"0.1-0.2","effect":"Drug-induced lupus"},{"rate":"1-2","effect":"Hypersensitivity reactions"},{"rate":"1-3","effect":"Gastrointestinal disturbance"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"INH is a prodrug that is activated by mycobacterial catalase-peroxidase (KatG) to form an INH-NAD adduct, which inhibits InhA, a key enzyme in mycolic acid synthesis. This disrupts the integrity of the mycobacterial cell wall, making it bactericidal. In preventive therapy, INH is administered to individuals with latent tuberculosis infection (LTBI) to prevent progression to active TB disease.","oneSentence":"Isoniazid (INH) preventive therapy inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, preventing the development of active tuberculosis in latently infected individuals.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:59.921Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Latent tuberculosis infection (LTBI) prevention in high-risk populations"},{"name":"Prevention of tuberculosis disease progression in tuberculin skin test or interferon-gamma release assay positive individuals"}]},"trialDetails":[{"nctId":"NCT05994742","phase":"PHASE3","title":"An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-07-15","conditions":"Severe Acute Malnutrition, HIV, Comorbidities and Coexisting Conditions","enrollment":674},{"nctId":"NCT07266805","phase":"PHASE3","title":"Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency","status":"RECRUITING","sponsor":"Pharvaris Netherlands B.V.","startDate":"2025-10-16","conditions":"Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)","enrollment":32},{"nctId":"NCT06153069","phase":"PHASE4","title":"Asymptomatic TB With Innovative Modified Short-course Regimens","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-11-21","conditions":"Tuberculosis","enrollment":426},{"nctId":"NCT06214910","phase":"NA","title":"ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa","status":"COMPLETED","sponsor":"University of Washington","startDate":"2024-02-20","conditions":"Tuberculosis, HIV I Infection","enrollment":301},{"nctId":"NCT07086820","phase":"NA","title":"Window Prophylaxis for Pediatric Tuberculosis Prevention Trial","status":"RECRUITING","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2025-10-27","conditions":"Tuberculosis Infection, Household Contacts, Children","enrollment":647},{"nctId":"NCT05122767","phase":"PHASE1, PHASE2","title":"Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2023-05-24","conditions":"Tuberculosis, HIV","enrollment":92},{"nctId":"NCT05118490","phase":"PHASE4","title":"Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2023-07-19","conditions":"HIV Seropositivity, Tuberculosis, Household Contact","enrollment":1000},{"nctId":"NCT05122026","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2024-01-17","conditions":"HIV Seropositivity, Pregnancy, Tuberculosis Infection","enrollment":252},{"nctId":"NCT03315962","phase":"NA","title":"Simplified Isoniazid Preventive Therapy Strategy to Reduce TB Burden","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2017-11-15","conditions":"Tuberculosis, HIV/AIDS","enrollment":163},{"nctId":"NCT06191692","phase":"PHASE3","title":"1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam","status":"NOT_YET_RECRUITING","sponsor":"Freundeskreis Für Internationale Tuberkulosehilfe e.V","startDate":"2025-08-01","conditions":"Tuberculosis Infection","enrollment":350},{"nctId":"NCT03785106","phase":"PHASE3","title":"Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals","status":"ACTIVE_NOT_RECRUITING","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2019-08-15","conditions":"HIV-infected Participants With Latent TB Infection in High TB Burden Country","enrollment":2500},{"nctId":"NCT06874725","phase":"PHASE4","title":"Latent Tuberculosis in Type 2 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2018-04-18","conditions":"Latent Tuberculosis Infection","enrollment":552},{"nctId":"NCT06281834","phase":"PHASE1","title":"Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-11-15","conditions":"Pediatric HIV Infection, Latent Tuberculosis","enrollment":25},{"nctId":"NCT06512831","phase":"NA","title":"Isoniazid Prophylaxis Based on Risk Factors of Tuberculosis in Living Kidney Transplantation Recipients","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2023-06-01","conditions":"Kidney Transplantation, Tuberculosis, Isoniazid Toxicity","enrollment":1348},{"nctId":"NCT06511180","phase":"","title":"Introduction of Dispersible 3HP Formulations for TB Preventive Treatment in Children: a Multi-country Evaluation","status":"NOT_YET_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2024-08","conditions":"TB - Tuberculosis, Household Contact, HIV","enrollment":1200},{"nctId":"NCT06484530","phase":"PHASE4","title":"Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis","status":"RECRUITING","sponsor":"Mahidol University","startDate":"2024-03-12","conditions":"Tuberculosis (TB), Isoniazid Toxicity, Rifampicin Toxicity","enrollment":116},{"nctId":"NCT00351702","phase":"PHASE3","title":"Preventive Therapy for Tuberculosis in HIV Infected Persons","status":"COMPLETED","sponsor":"Tuberculosis Research Centre, India","startDate":"2001-02","conditions":"Human Immunodeficiency Virus, Tuberculosis","enrollment":683},{"nctId":"NCT04094012","phase":"PHASE3","title":"Risk of SDRs Under 3HP and 1HP Regimen for LTBI","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2019-09-24","conditions":"Latent Tuberculosis Infection","enrollment":490},{"nctId":"NCT03302299","phase":"PHASE4","title":"Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2017-04-07","conditions":"Tuberculosis, HIV/AIDS, Alcohol Abuse","enrollment":302},{"nctId":"NCT04600167","phase":"PHASE3","title":"Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus","status":"UNKNOWN","sponsor":"Dr. Nyanda Elias Ntinginya","startDate":"2022-06-17","conditions":"Diabetes Mellitus, Tuberculosis","enrollment":3000},{"nctId":"NCT03832023","phase":"NA","title":"Community-based Tuberculosis Tracing and Preventive Therapy","status":"COMPLETED","sponsor":"Elizabeth Glaser Pediatric AIDS Foundation","startDate":"2019-10-14","conditions":"Tuberculosis","enrollment":1400},{"nctId":"NCT03435146","phase":"PHASE1, PHASE2","title":"Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventive Therapy in HIV+ Patients (DOLPHIN & DOLPHIN TOO)","status":"COMPLETED","sponsor":"The Aurum Institute NPC","startDate":"2018-01-18","conditions":"Respiratory Tract Infections, HIV Infections","enrollment":135},{"nctId":"NCT05085171","phase":"PHASE3","title":"An Enhanced Package of Care to Reduce Reduce Mortality in Advanced HIV Disease","status":"RECRUITING","sponsor":"Makerere University","startDate":"2022-05-04","conditions":"The Study Will Focus on Assessing the Survival Benefit on an Enhanced Package of Care for Patients With Advanced HIV Disease","enrollment":2400},{"nctId":"NCT05249699","phase":"NA","title":"The Prophylaxis of Tuberculosis According to TSPOT Results After Kidney Transplantation","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2022-04-01","conditions":"Kidney Transplant Infection, Tuberculosis, Isoniazid Toxicity","enrollment":303},{"nctId":"NCT03417102","phase":"PHASE3","title":"A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2018-02-14","conditions":"Hemophilia A, Hemophilia B","enrollment":60},{"nctId":"NCT01494038","phase":"PHASE4","title":"Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-08-19","conditions":"HIV Infections, Tuberculosis","enrollment":956},{"nctId":"NCT00000959","phase":"NA","title":"Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Tuberculosis","enrollment":600},{"nctId":"NCT00000636","phase":"NA","title":"Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Tuberculosis","enrollment":2000},{"nctId":"NCT00000638","phase":"NA","title":"Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Tuberculosis","enrollment":2000},{"nctId":"NCT02383849","phase":"","title":"IMPAACT P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2015-08-04","conditions":"Low-Birth-Weight Infant, Tuberculosis, HIV","enrollment":124},{"nctId":"NCT01926379","phase":"NA","title":"ENhance Initiation and Retention in Isoniazid Preventive Therapy (IPT) Care for HIV Study (ENRICH Study)","status":"COMPLETED","sponsor":"Columbia University","startDate":"2013-07","conditions":"HIV, Tuberculosis","enrollment":338},{"nctId":"NCT00914966","phase":"PHASE4","title":"A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE","status":"COMPLETED","sponsor":"Shire","startDate":"2009-08-31","conditions":"Hereditary Angioedema","enrollment":20},{"nctId":"NCT03723525","phase":"PHASE4","title":"Package of Care to Improve Retention in ART and Mortality Among Treatment Naive HIV Infected Individuals","status":"COMPLETED","sponsor":"National Centre for AIDs and STD Control, Nepal","startDate":"2018-01-22","conditions":"HIV","enrollment":1073},{"nctId":"NCT04528277","phase":"PHASE3","title":"Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2020-09-01","conditions":"Infertility, Female, Recurrent Implantation Failure, Genital Tuberculoses, Female","enrollment":1050},{"nctId":"NCT02430259","phase":"PHASE3","title":"Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention","status":"COMPLETED","sponsor":"Huashan Hospital","startDate":"2015-03","conditions":"Silicosis, Tuberculosis","enrollment":566},{"nctId":"NCT03910946","phase":"","title":"Prevalence of Latent Tuberculosis in High Risk Children","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2020-07-01","conditions":"Latent Tuberculosis","enrollment":100},{"nctId":"NCT03074799","phase":"NA","title":"Nurse-Led, Symptom-Based Screening of Household Child Contacts of Tuberculosis Index Cases","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2015-10-01","conditions":"Tuberculosis","enrollment":4054},{"nctId":"NCT03028129","phase":"PHASE4","title":"Prevention of Tuberculosis in Prisons","status":"TERMINATED","sponsor":"Federal University of Mato Grosso","startDate":"2017-09-04","conditions":"Tuberculosis, Pulmonary, Antibiotic Prophylaxis","enrollment":467},{"nctId":"NCT00330304","phase":"PHASE3","title":"Isoniazid Prophylaxis With Concomitant Cotrimoxazole in HIV-infected Children","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2003-01","conditions":"Tuberculosis","enrollment":450},{"nctId":"NCT03900858","phase":"NA","title":"Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis(SCRIPT-TB)","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2018-12-01","conditions":"Silicosis Tuberculosis","enrollment":566},{"nctId":"NCT00080119","phase":"PHASE2, PHASE3","title":"Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV","status":"TERMINATED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2004-02","conditions":"HIV Infection, Tuberculosis, Pneumocystis Jiroveci Pneumonia","enrollment":1354},{"nctId":"NCT02316353","phase":"PHASE3","title":"A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2014-12-31","conditions":"Hereditary Angioedema Types I and II","enrollment":126},{"nctId":"NCT02208427","phase":"PHASE3","title":"Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2014-08","conditions":"Latent Tuberculosis Infection","enrollment":283},{"nctId":"NCT01223534","phase":"PHASE4","title":"QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.","status":"COMPLETED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2010-07","conditions":"Latent Tuberculosis Infection","enrollment":871},{"nctId":"NCT01825031","phase":"PHASE3","title":"Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy","status":"COMPLETED","sponsor":"Anna Griffiths, MRC","startDate":"2013-06","conditions":"Human Immunodeficiency Virus","enrollment":1805},{"nctId":"NCT00495651","phase":"PHASE3","title":"Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2008-03","conditions":"HIV Infections, Tuberculosis","enrollment":2073},{"nctId":"NCT01761201","phase":"PHASE3","title":"\"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients\".","status":"TERMINATED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2012-01","conditions":"Latent Tuberculosis Infection, Infection in Solid Organ Transplant Recipients","enrollment":68},{"nctId":"NCT00164281","phase":"PHASE4","title":"Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2004-11","conditions":"Tuberculosis, HIV Infections","enrollment":2000},{"nctId":"NCT00850915","phase":"PHASE4","title":"Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya","status":"COMPLETED","sponsor":"KNCV Tuberculosis Foundation","startDate":"2009-04","conditions":"Tuberculosis","enrollment":1259},{"nctId":"NCT00057122","phase":"PHASE3","title":"Tuberculosis Prevention for HIV Infected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-09","conditions":"HIV Infections, Tuberculosis","enrollment":1148},{"nctId":"NCT00463086","phase":"NA","title":"Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2007-11","conditions":"Tuberculosis, Latent Tuberculosis Infection, HIV Infections","enrollment":1368},{"nctId":"NCT01398618","phase":"PHASE3","title":"Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI)","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2011-05","conditions":"Latent Tuberculosis Infection","enrollment":300},{"nctId":"NCT00107887","phase":"PHASE4","title":"TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2005-06","conditions":"Tuberculosis, HIV Infections","enrollment":17415},{"nctId":"NCT00402454","phase":"PHASE4","title":"Evaluation of Three Regimens of Chemoprophylaxis for Tuberculosis in Patients co-Infected by HIV and Mycobacterium Tuberculosis","status":"COMPLETED","sponsor":"Sociedad Andaluza de Enfermedades Infecciosas","startDate":"1994-01","conditions":"HIV Infections","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"INH preventive therapy","genericName":"INH preventive therapy","companyName":"Johns Hopkins University","companyId":"johns-hopkins-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Isoniazid (INH) preventive therapy inhibits mycobacterial cell wall synthesis by blocking mycolic acid production, preventing the development of active tuberculosis in latently infected individuals. Used for Latent tuberculosis infection (LTBI) prevention in high-risk populations, Prevention of tuberculosis disease progression in tuberculin skin test or interferon-gamma release assay positive individuals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}